Welcome to our dedicated page for Semler Scientific news (Ticker: SMLR), a resource for investors and traders seeking the latest updates and insights on Semler Scientific stock.
Semler Scientific, Inc. reports corporate news around its Bitcoin treasury strategy and its medical-device and software business. Company updates have described Bitcoin as the primary treasury reserve asset, with recurring disclosures on Bitcoin purchases, holdings, BTC Yield and related financing activity through equity, debt and operating cash flow.
Semler Scientific news also covers healthcare initiatives, including QuantoFlo device and software for early detection of peripheral artery disease and CardioVanta, a wholly owned subsidiary focused on early detection of heart failure and cardiac arrhythmia monitoring. Other recurring items include operating results, board and strategy roles, capital-structure updates and shareholder matters.
Semler Scientific, Inc. (Nasdaq: SMLR) has announced it will release its financial results for the third quarter and first nine months of 2022 on November 1, 2022, after U.S. market close. The CEO, Doug Murphy-Chutorian, will lead a conference call at 4:30 pm ET that day, featuring senior executives from the company. Semler Scientific specializes in technology solutions for healthcare, including the FDA-cleared QuantaFlo® test for cardiovascular diseases. They also market Insulin Insights™ and are developing new products to enhance patient care.
Santa Clara, Calif., Aug. 31, 2022 /PRNewswire/ -- Semler Scientific (Nasdaq: SMLR) announced that Renae Cormier, Head of Corporate Communications and Business Strategy, will present at three upcoming investor conferences. The events include the H.C. Wainwright 24th Annual Global Investment Conference on September 12, Lake Street 6th Annual Best Ideas Growth Conference on September 14, and the 7th Annual MicroCap Leadership Summit on September 16. Semler specializes in technology solutions for healthcare, notably with its QuantaFlo® diagnostic tool for cardiovascular diseases.
Semler Scientific (SMLR) reported Q2 2022 revenues of $14.8 million, a 4% increase from Q2 2021. Net income fell by 39% to $4.1 million, or $0.60 per basic share. The company achieved its highest quarterly revenues and cash on hand, totaling $40.0 million. Operating expenses rose to 65% of revenues at $9.6 million, reflecting a 23% increase. For 2022, guidance predicts revenues between $58.0 million and $60.0 million, with an operating expense range of $42.5 million to $44.0 million.
Semler Scientific, Inc. (Nasdaq: SMLR) will report its financial results for the second quarter and first half of 2022 on August 2, 2022, after U.S. market close. CEO Doug Murphy-Chutorian will lead a conference call at 4:30 pm ET the same day. Key executives will also participate in the call, which can be accessed via pre-registration or direct dialing. Semler focuses on technology solutions for healthcare efficiency, with FDA-cleared products like QuantaFlo® aiding in chronic disease diagnosis.
Semler Scientific reported its financial results for Q1 2022. Revenues increased by $0.8 million (6%) to $14.0 million. However, net income fell 31% to $3.4 million, with earnings per share at $0.50 for basic shares. Cash reserves rose significantly to $38.4 million. The company remains committed to profitability and expects Q2 revenues between $14.2 million and $15.2 million.
Semler Scientific (Nasdaq: SMLR) will report its first-quarter financial results for 2022 on May 2, 2022, after U.S. market close. A conference call hosted by CEO Doug Murphy-Chutorian and other executives will follow at 4:30 PM ET. Semler focuses on technology solutions that enhance the clinical effectiveness of healthcare providers, including its FDA-cleared product, QuantaFlo®, which aids in diagnosing peripheral arterial disease. This product helps evaluate patients at risk for heart attacks and strokes.
Semler Scientific, a leader in healthcare technology solutions, announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 13 at 1:30 pm ET. CEO Doug Murphy-Chutorian and CMO Dennis Rosenberg will present a company overview and engage in one-on-one calls with investors. A live webcast of the event will be available on the Semler Scientific website under the 'Events and Presentations' section, with an archived version accessible for 90 days post-conference. Semler's flagship product, QuantaFlo®, aids in diagnosing peripheral arterial disease.
Semler Scientific (Nasdaq: SMLR) has announced a $20 million stock repurchase program approved by its board of directors. This program allows the company to buy back shares through various means, with no specified expiration date or minimum purchase requirement. CEO Doug Murphy Chutorian expressed confidence in the company’s financial strength and future prospects. Semler focuses on technology solutions to enhance healthcare, including the FDA-cleared QuantaFlo® product for assessing arterial blood flow.
Semler Scientific (Nasdaq: SMLR) announced a published study in the Journal of Vascular Surgery demonstrating the effectiveness of QuantaFlo® in screening for undetected peripheral artery disease (PAD) among 13,971 Medicare Advantage patients. The study found a 31.6% positive rate for PAD and highlighted significant associated risks, including a 60-70% increased risk of all-cause mortality at one year. The findings advocate for early PAD screening, potentially boosting adoption of QuantaFlo® among healthcare providers, according to CEO Doug Murphy-Chutorian.
Semler Scientific (Nasdaq: SMLR) reported a 37% increase in annual revenues to $53.0 million for 2021, compared to $38.6 million in 2020. Net income rose by 23% to $17.2 million, translating to $2.56 per basic share. However, Q4 revenue dipped 4% year-over-year to $11.5 million, with net income dropping 72% to $1.5 million. Notably, the cost of revenues surged 120% in Q4, reflecting a $1.2 million inventory write-down. Despite these challenges, the company maintains a optimistic outlook for continued profitability and growth.